| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE39593 | COLLEGIUM PHARM INC | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug, 2022
(1 year, 1 month ago) | |
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(1 year, 8 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11007156 | COLLEGIUM PHARM INC | Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol |
Oct, 2022
(11 months ago) | |
| US8309060 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Nov, 2023
(a month from now) | |
| US8075872 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Nov, 2023
(a month from now) | |
| US8420056 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Nov, 2023
(a month from now) | |
| US8114383 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Oct, 2024
(1 year, 7 days from now) | |
| US11344512 | COLLEGIUM PHARM INC | Titration of tapentadol |
Apr, 2028
(4 years from now) | |
| US8536130 | COLLEGIUM PHARM INC | Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain |
Sep, 2028
(4 years from now) | |
Nucynta Er is owned by Collegium Pharm Inc.
Nucynta Er contains Tapentadol Hydrochloride.
Nucynta Er has a total of 9 drug patents out of which 2 drug patents have expired.
Expired drug patents of Nucynta Er are:
- US11007156
- USRE39593
Nucynta Er was authorised for market use on 25 August, 2011.
Nucynta Er is available in tablet, extended release;oral dosage forms.
Nucynta Er can be used as relief of moderate to severe chronic pain; management of neuropathic pain associated with diabetic peripheral neuropathy, management of neuropathic pain associated with diabetic peripheral neuropathy, a method of titrating an opioid to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatments are inadequate; a method of titrating an opioid to manage neuropathic pain associated with diabetic peripheral neuropathy severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate, management of neuropathic pain associated with diabetic peripheral neuropathy; relief of moderate to severe chronic pain.
The generics of Nucynta Er are possible to be released after 22 September, 2028.
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
Market Authorisation Date: 25 August, 2011
Treatment: Relief of moderate to severe chronic pain; Management of neuropathic pain associated with diabetic peripheral neuropathy; A method of titrating an opioid to manage pain severe enough to require daily,...
Dosage: TABLET, EXTENDED RELEASE;ORAL
NUCYNTA ER family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic